

D1
106. (Once Amended) The non-human monoclonal antibody or a portion thereof according to claim 104, wherein said monoclonal antibody comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by international deposit accession No. FERM BP-6208.

107. (Once Amended) The non-human monoclonal antibody or a portion thereof according to claim 104, wherein said monoclonal antibody is produced by a hybridoma identified by international deposit accession No. FERM BP-6209.

108. (Once Amended) The non-human monoclonal antibody or a portion thereof according to claim 104, wherein said monoclonal antibody comprises a property substantially equivalent to that of a monoclonal antibody produced by a hybridoma identified by international deposit accession No. FERM BP-6209.

Please cancel claims 109-120

6
121. (Once Amended) A cell producing the non-human monoclonal antibody according to claim 104.

Please cancel claim 122.

123. (Once Amended) The cell according to claim 121, wherein said cell is a hybridoma obtainable by fusing a mammalian myeloma cell with a mammalian B cell which is capable of producing the non-human monoclonal antibody.

Please cancel claims 124-126.

127. (Once Amended) The cell according to claim 121, wherein said cell is a hybridoma identified by international deposit accession numbers selected from the group consisting of FERM

BP-6208 and FERM BP-6209.

2 128. (Once Amended) An antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized.

10
129. (Once Amended) The non-human antibody-immobilized insoluble carrier according to claim 128, wherein said insoluble carrier is selected from the group consisting of plates, test tubes, tubes, beads, balls, filters and membranes.

11
130. (Once Amended) The non-human antibody-immobilized insoluble carrier according to claim 128, wherein said insoluble carrier is a filter or membrane, ~~or that used~~ for affinity column chromatography.

131. (Once Amended) A labeled antibody which is prepared by labeling the non-human monoclonal antibody or a portion thereof according to claim 104 with a labeling agent capable of providing a detectable signal by itself or together with other substances.

13
132. (Once Amended) The labeled non-human antibody according to claim 131, wherein said labeling agent is an enzyme, fluorescent substance, chemiluminescent substance, biotin, avidin, or radioisotope.

133. (Once Amended) A kit for detecting or assaying mammalian CTGF, comprising the non-human monoclonal antibody or a portion thereof according to claim 104.

134. (Once Amended) A kit for detecting or assaying mammalian CTGF comprising an antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized.

3 135. (Once Amended) A kit for detecting or assaying mammalian CTGF comprising a labeled antibody which is prepared by labeling the non-human monoclonal antibody or a portion thereof according to claim 104 with a labeling agent capable of providing a detectable signal by itself or together with other substances.

136. (Once Amended) A method for detecting or assaying mammalian CTGF by an immunoassay, comprising at least the following steps of (a) and (b):

(a) reacting a sample with an antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized; and,

C4 (b) reacting a labeled antibody which is prepared by labeling the monoclonal antibody or a portion thereof according to claim 104 with a labeling agent capable of providing a detectable signal by itself or together with other substances, with an antigen-antibody complex formed by binding mammalian CTGF in said sample to the antibody-immobilized insoluble carrier.

137. (Once Amended) A method for detecting or assaying mammalian CTGF by an immunoassay, comprising at least the following steps of (a) and (b):

(a) reacting a sample with a labeled antibody which is prepared by labeling the monoclonal antibody or a portion thereof according to claim 104 with a labeling agent capable of providing a detectable signal by itself or together with other substances; and,

(b) reacting an antibody-immobilized insoluble carrier on which the monoclonal antibody according to claim 104 is immobilized, with the antigen-antibody complex formed by binding said labeled antibody and mammalian CTGF in said sample.

138. (Once Amended) A method for detecting or assaying mammalian CTGF by an immunoassay, comprising at least the following step of (a):

(a) reacting a mixture comprising an antibody-immobilized insoluble carrier on which the monoclonal antibody according to claim 104 is immobilized, a labeled antibody which is prepared by labeling the monoclonal antibody or a portion thereof according to claim 104 with a labeling agent capable of providing a detectable signal by itself or together with other substances, and a sample.

139. (Once Amended) A method for detecting or assaying mammalian CTGF by an immunoassay, comprising at least the following step of (a):

(a) reacting a sample and a mammalian CTGF standard labeled with a labeling agent capable of providing a detectable signal by itself or together with other substances, with an antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized.

140. (Once Amended) A method for detecting or assaying mammalian CTGFs by an immunoassay, comprising at least the following steps of (a) and (b):

(a) reacting the non-human monoclonal antibody or a portion thereof according to claim 104 with a mixture comprising a sample and a mammalian CTGF standard labeled with a labeling agent capable of providing a detectable signal by itself or together with other substances; and,

CY (b) reacting a mammalian antiserum reactive to said monoclonal antibody with the antigen-antibody complex formed by binding mammalian CTGF in said sample or said labeled mammalian CTGF standard and said monoclonal antibody.

141. (Once Amended) A method for detecting or assaying mammalian CTGFs by an immunoassay, comprising at least the following steps of any of (a) to (c):

(a) reacting the non-human monoclonal antibody or a portion thereof according to claim 104 with a sample;

(b) reacting a mammalian CTGF standard labeled with a labeling agent capable of providing a detectable signal by itself or together with other substances with a reaction product resulted from the reaction in step (a); and,

(c) reacting a mammalian antiserum reactive to said monoclonal antibody with the antigen-antibody complex formed by binding mammalian CTGF in said sample or said labeled mammalian CTGF standard, and said monoclonal antibody.

Sub 142. (Once Amended) A kit for separating or purifying mammalian CTGF, comprising an antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized.

143. ~~(Once Amended)~~ A method for separating or purifying mammalian CTGF, comprising using affinity chromatography with an antibody-immobilized insoluble carrier on which the non-human monoclonal antibody according to claim 104 is immobilized.

c4 144. ~~(Once Amended)~~ The method for separating or purifying mammalian CTGF according to claim 143, wherein said affinity chromatography is affinity column chromatography.

Please cancel claims 145-154.

Please add the following new claim 155.

c5 155. ~~(New)~~ The non-human monoclonal antibody or a portion thereof according to claim 104, said non-human monoclonal antibody characterized by inhibiting the binding of human CTGF to human kidney-derived fibroblast cell line 293-T (ATCC CRL1573).
